Gadavist is used intravenously to conduct MRI in adults and children (2 years and above) to detect the abnormal vascularity of the Central Nervous System and view the areas with a blood-brain barrier. It is a gadolinium-based contrast agent that is also used for breast MRI, which would help detect the disease and evaluate to what extent it has spread inside the body.
It is regarded as an essential tool for healthcare professionals dealing with breast cancer patients, which would help in choosing the form of therapy that can bring about the best response. It can also be used in adults who have been diagnosed (or suspected) with Coronary artery disease to assess the myocardial perfusion and late gadolinium enhancement. For magnetic resonance angiography or MRA, Gadavist is useful for evaluating supra-aortic or renal artery disease in both adults and children. The safety profile this agent has also been established through effective clinical trials, conducted on 7713 patients that involve both pediatric patients and adults. The healthcare industry has achieved another milestone with Gadavist finally gaining approval from the US Food and Drug Administration. The Imaging Bulk Package is available in two sizes – 30ml and 65ml. So far, it has been planned to be used across several patients, and work shifts up to 24 hours after the first puncture of the Imaging Bulk Package. The company has also claimed that the bulk package has a high chance of complete usage that would automatically lead to fewer vials getting wasted. Not only that, but the bulk package has also stayed true to the Joint Commission requirements to multi-patient dosing. Apart from that, the MEDRAD® Imaging Bulk Package Transfer Spike has also been cleared by the FDA for the transfer of Gadavist contrast media as supplied in the Imaging Bulk Package Presentation. It is the one and only FDA-approved Imaging Bulk Package MR contrast media for use that offers a series of key features to support radiology workflow. By utilizing a single multi-dose setup directly in the scan room, it is also possible for technologists and nurses to prepare as well as administer weight-based dosing. The Head of Region Americas, Bayer Radiology, claimed that the ever-changing dynamics of the healthcare environment had led them to dedicate and invest in innovative solutions that will be able to address the challenges and the unmet needs of the hospitals. Sourece url: https://www.businesswire.com/news/home/20200813005263/en/FDA-Approves-Gadavist%C2%AE-gadobutrol-Imaging-Bulk-Package Read:- All about Benign Prostatic Hyperplasia (BPH)
0 Comments
Leave a Reply. |
Details
ArchivesAuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |